T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …

Multiple myeloma is an incurable cancer characterized by the uncontrolled growth of
malignant plasma cells nurtured within a permissive bone marrow microenvironment. While …

B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates
multiple myeloma (MM) resistance to anti-BCMA chimeric antigen receptor T cell (CAR T) or …

Bispecific T cell engagers (TCEs) have shown promise in the treatment of various cancers,
but the immunological mechanism and molecular determinants of primary and acquired …

Despite recent advances in immunotherapies targeting single tumor-associated antigens,
patients with multiple myeloma eventually relapse. ISB 2001 is a CD3+ T cell engager (TCE) …

The treatment paradigm in myeloma is constantly changing. Upfront use of monoclonal
antibodies like daratumumab along with proteasome inhibitors (PI) s, and immune …

Bispecific antibodies are monoclonal antibodies targeting both a surface molecule on the
malignant plasma cells and CD3 on T cells, leading to tumor cell death by activated T cells …

The treatment of multiple myeloma (MM) is evolving rapidly. In the past few years, chimeric
antigen receptor modified T cells and bispecific antibodies are bringing new treatment …

Simple Summary Multiple myeloma, a cancer of the bone marrow, is the commonest cancer
of adults in the Western World. Therapies have advanced dramatically in recent years …

A better understanding of the roles of the adaptive and innate immune systems in the
oncogenesis of cancers including multiple myeloma (MM) has led to the development of …